Oncology
1 drug is in development for Breast Neoplasms.
- Companies
- 1
- Clinical trials
- 38
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Breast Neoplasms pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| -endoxifen | ATOSSA THERAPEUTICS, INC. (ATOS) |
About this indication
Breast Neoplasms context
Oncology·MeSH: Breast Neoplasms (D001943)
Also known as: Breast Neoplasm, Breast Tumor, Breast Tumors
Narrower concepts tracked separately: Breast Cancer, Breast Carcinoma
Prevalence
287.0 / 100K
Incidence
128.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Breast Neoplasms?
BioSniper tracks 1 drug in development for Breast Neoplasms across 1 company.
How many clinical trials target Breast Neoplasms?
There are 38 clinical trials targeting Breast Neoplasms tracked by BioSniper.
What is the prevalence of Breast Neoplasms?
The estimated prevalence of Breast Neoplasms is approximately 287.0 per 100,000 population.